IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Supernus Pharmaceuticals Inc

CUSIP: 868459AB4 | 10 institutional holders

Quarters

Q2 2017Q1 2017Q4 2016Q3 2016Q2 2016
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q2 2017

Goldman Sachs Group Inc50,000
0.0% of portfolio›$407
Wells Fargo & Company25,000
0.0% of portfolio›$203
StyleTurnoverLocationFiled
Goldman Sachs Group Inc
50,000$4070.0%CoreMediumNew York, NY2017-08-14
Wells Fargo & Company
25,000$2030.0%CoreLowSan Francisco, CA2017-08-10